Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4499 - Ability of TMPRSS2-ERG (TE) expression to predict taxane benefit depending on prior abiraterone or enzalutamide therapy in castration-resistant prostate cancer

Date

11 Sep 2017

Session

Poster display session

Topics

Translational Research;  Prostate Cancer

Presenters

Mercedes Marín-Aguilera

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

M. Marín-Aguilera1, O. Reig1, A. Font2, A. Rodríguez-Vida3, C. Suárez4, M. Domenech5, N. Jiménez1, I. Victoria1, S. López1, M. Milà-Guasch1, E. Felip2, O. Etxaniz2, J. Carles4, F. Racca4, N. Sala-González6, A. González del Alba7, P.L. Fernández8, A. Prat1, B. Mellado1

Author affiliations

  • 1 Medical Oncology/translational Genomics And Targeted Therapeutics In Solid Tumors Lab, Hospital Clínic of Barcelona/Institut d'Investigacions Biomèdiques Agust Pi i Sunyer/Fundació Clínic per a la Recerca Biomèdica, 08036 - Barcelona/ES
  • 2 Medical Oncology, Institut Català d'Oncologia, Badalona/ES
  • 3 Medical Oncology, Hospital del Mar, Barcelona/ES
  • 4 Medical Oncology, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona/ES
  • 5 Medical Oncology, Fundació Althaia, Barcelona/ES
  • 6 Medical Oncology, Institut Català d'Oncologia, Girona/ES
  • 7 Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca/ES
  • 8 Medical Oncology/translational Genomics And Targeted Therapeutics In Solid Tumors Lab, Hospital Clínic of Barcelona/Institut d'Investigacions Biomèdiques Agust Pi i Sunyer, 08036 - Barcelona/ES
More

Resources

Abstract 4499

Background

TMPRSS2-ERG (TE) results in androgen-driven overexpression of ERG, which is involved in resistance to taxanes in preclinical models. In prior work we showed that TE expression in blood correlated with taxanes resistance in metastatic castration-resistant prostate cancer (mCPRC). Here, we studied if the detection of TE in primary tumors predicts taxanes activity in CPRC. We also explored the impact of prior abiraterone or enzalutamide (A/E) in blood TE detection and in TE predictive value.

Methods

mCRPC patients (pts) treated with taxanes in a multicenter biomarker study were included. Formalin-fixed paraffin-embedded (FFPE) tumors and peripheral blood mononuclear cells (PBMCs) fraction were tested for TE presence by RT-qPCR. FFPE were retrospectively obtained. PBMCs were prospectively collected prior to taxane initiation. PSA-PFS was evaluated by Kaplan-Meier analysis using log-rank test. Univariate analysis of TE status (+ vs-) was performed with Cox regression.

Results

124 pts were included: 111 (89.5%) received docetaxel (Dx), 13 (10.5%) cabazitaxel (Cz) and 27 (21.8%) both. Fifty-seven (45.9%) tumors were TE+. Overall, no correlation between tumor TE expression and taxane benefit was observed in the whole population, or in the Dx or Cz group separately. However, in Dx-treated pts without prior A/E (N = 80, 72.1%), tumor TE+ correlated with lower PSA-PFS (median 8.6 vs 13.6 months; HR 1.7, p ≤ 0.05). No differences were observed in Dx treated pts with prior A/E (N = 31, 27.9%) according to tumor TE expression. In 44 pts, matched tumor and PBMC samples were available. Concordance between tumor an blood was 92.8% and 63.3% for pts with and without prior A/E, respectively. TE in blood was + in 1 (7%) pts with prior A/E and in 7 (23.3%) pts without prior A/E. As observed in FFPE samples, in patients without prior A/E to Dx (N = 28; 63.6%), blood TE+ correlated with lower PSA response (0% vs 61.9%, p ≤ 0.01) and reduced median PSA-PFS (3.34 vs 8.2 mM; HR 4.1 p ≤ 0.01).

Conclusions

The predictive value of TE in taxane resistance may be different depending on prior exposure to A/E. This is being tested in a multicenter prospective study.

Clinical trial identification

Legal entity responsible for the study

Hospital Clínic of Barcelona/Institut d'Investigacions Biomèdiques Agust Pi i Sunyer

Funding

None

Disclosure

A. González del Alba: Advisory boards: Sanofi, Janssen, Astellas, Bayer Travel expenses: Astellas, Sanofi, Janssen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.